JP2008532936A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008532936A5 JP2008532936A5 JP2007555332A JP2007555332A JP2008532936A5 JP 2008532936 A5 JP2008532936 A5 JP 2008532936A5 JP 2007555332 A JP2007555332 A JP 2007555332A JP 2007555332 A JP2007555332 A JP 2007555332A JP 2008532936 A5 JP2008532936 A5 JP 2008532936A5
- Authority
- JP
- Japan
- Prior art keywords
- signaling
- heterodimer
- protein
- seq
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65326005P | 2005-02-14 | 2005-02-14 | |
| US66749205P | 2005-04-01 | 2005-04-01 | |
| PCT/US2006/005111 WO2006088833A2 (en) | 2005-02-14 | 2006-02-14 | Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008532936A JP2008532936A (ja) | 2008-08-21 |
| JP2008532936A5 true JP2008532936A5 (cg-RX-API-DMAC7.html) | 2009-04-02 |
Family
ID=36592866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007555332A Withdrawn JP2008532936A (ja) | 2005-02-14 | 2006-02-14 | インターロイキン−17f抗体及び他のil−17fシグナル伝達拮抗物質並びにそれらの使用 |
Country Status (18)
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070160576A1 (en) * | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
| AU2004235396B2 (en) | 2003-04-29 | 2010-11-25 | Sarepta Therapeutics, Inc. | Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells |
| DK1641822T3 (da) * | 2003-07-08 | 2013-07-22 | Genentech Inc | Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf. |
| US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| EP1765865A2 (en) | 2004-06-10 | 2007-03-28 | ZymoGenetics, Inc. | Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation |
| GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| WO2006088925A2 (en) * | 2005-02-14 | 2006-08-24 | Wyeth | Use of il17-f in diagnosis and therapy of airway inflammation |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| DE602006009834D1 (de) | 2005-09-01 | 2009-11-26 | Schering Corp | Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung |
| WO2007117762A1 (en) * | 2006-02-10 | 2007-10-18 | Zymogenetics, Inc. | Truncated il-17ra soluble receptor and methods of using in inflammation |
| WO2008039553A1 (en) * | 2006-02-10 | 2008-04-03 | Zymogenetics, Inc. | Soluble il-17rcx4 and methods of using in inflammation |
| US7790163B2 (en) | 2006-03-10 | 2010-09-07 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
| US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| JP2009534297A (ja) * | 2006-03-10 | 2009-09-24 | ザイモジェネティクス, インコーポレイテッド | Il−17aおよびil−17fの両方に結合する抗体ならびにその使用方法 |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
| FR2908999B1 (fr) * | 2006-11-29 | 2012-04-27 | Biomerieux Sa | Nouveau medicament destine a l'inhibition, la prevention ou le traitement de la polyarthrite rhumatoide. |
| FR2910324B1 (fr) * | 2006-12-21 | 2009-03-06 | Biomerieux Sa | Nouveau medicament pour le traitement d'un cancer gastrique |
| TW200902064A (en) * | 2007-03-28 | 2009-01-16 | Wyeth Corp | Methods and compositions for modulating IL-17F/IL-17A biological activity |
| AU2007352412B2 (en) * | 2007-04-27 | 2013-05-16 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
| BRPI0813262A2 (pt) * | 2007-06-20 | 2015-04-14 | Schering Corp | Biomarcadores de destruição de articulação para terapia de doença inflamatória de articulação anti-il-17a |
| EP2170392A2 (en) | 2007-06-28 | 2010-04-07 | Opsona Therapeutics Limited | Composition and method for treatment of autoimmune disease |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| EP2182943B1 (en) * | 2007-07-23 | 2016-10-26 | Janssen Biotech, Inc. | Methods and compositions for treating fibrosis related disorders using il-17 antagonists |
| CN101361968B (zh) | 2007-08-06 | 2011-08-03 | 健能隆医药技术(上海)有限公司 | 白介素-22在治疗脂肪肝中的应用 |
| EP2203476B1 (en) | 2007-09-25 | 2016-10-26 | Genzyme Corporation | Compositions and methods for inhibiting interleukin pathways |
| EP2106801A1 (en) | 2008-04-04 | 2009-10-07 | Giuliani International Limited | IL-25 for use in the treatment of inflammatory diseases |
| GB0807413D0 (en) | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
| BRPI0908312A2 (pt) * | 2008-05-05 | 2015-08-18 | Novimmune Sa | '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular'' |
| EP2130547A1 (en) | 2008-06-06 | 2009-12-09 | Giuliani International Limited | IL-25 for use in the treatment of inflammatory diseases |
| WO2010008001A1 (ja) | 2008-07-14 | 2010-01-21 | 国立大学法人 東京大学 | Il-17に対するアプタマー及びその使用 |
| TW201018482A (en) * | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
| EP2353004B1 (en) | 2008-11-12 | 2018-01-03 | Yeda Research and Development Co. Ltd. | Diagnosis of multiple sclerosis |
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| NZ594514A (en) | 2009-03-05 | 2013-06-28 | Abbott Lab | Interleukin-17 BINDING PROTEINS |
| EP2427203B1 (en) * | 2009-05-05 | 2018-10-17 | Novimmune S.A. | Anti-il-17f antibodies and use thereof |
| WO2010142551A2 (en) * | 2009-06-12 | 2010-12-16 | Ablynx N.V. | Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family |
| JP2013525820A (ja) * | 2010-05-06 | 2013-06-20 | シングレクス、インコーポレイテッド | 関節リウマチの発症に関するリスクを診断し、病期分類し、予測し、治療レスポンダーを同定するための方法 |
| EP3023496B1 (en) * | 2010-05-13 | 2020-07-29 | Sarepta Therapeutics, Inc. | Compounds which modulate interleukins 17 and 23 signaling activity |
| US9932403B2 (en) | 2010-05-20 | 2018-04-03 | Ablynx Nv | Biological materials related to HER3 |
| CN102380091A (zh) | 2010-08-31 | 2012-03-21 | 健能隆医药技术(上海)有限公司 | 白介素-22在治疗病毒性肝炎中的应用 |
| WO2012085099A1 (en) * | 2010-12-21 | 2012-06-28 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Determination of the efficacy of an anti-mycobacterial vaccination |
| PH12013501435B1 (en) | 2011-01-14 | 2019-02-01 | UCB Biopharma SRL | Antibody molecules which bind il-17a and il-17f |
| US20120251524A1 (en) * | 2011-04-01 | 2012-10-04 | Baxter Healthcare S.A. | Use of cytokine levels in intravenous immunoglobulin treatment of alzheimer's disease |
| EP2699256B1 (en) * | 2011-04-21 | 2017-09-27 | The Regents of the University of Colorado, a body corporate | Compositions and methods for the treatment of neuromyelitis optica |
| US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| CN103182072B (zh) | 2011-12-27 | 2017-05-03 | 健能隆医药技术(上海)有限公司 | 白介素‑22在治疗和预防神经损伤疾病或神经退行性疾病中的用途 |
| EP2809660B1 (en) | 2012-02-02 | 2016-01-20 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating il-17 |
| AR091116A1 (es) | 2012-05-22 | 2015-01-14 | Bristol Myers Squibb Co | Anticuerpos biespecificos y sus metodos de uso |
| JP2015222174A (ja) * | 2012-09-13 | 2015-12-10 | 学校法人 久留米大学 | 炎症性疾患を処置するため薬剤のスクリーニング方法 |
| US10260089B2 (en) | 2012-10-29 | 2019-04-16 | The Research Foundation Of The State University Of New York | Compositions and methods for recognition of RNA using triple helical peptide nucleic acids |
| CA2907636C (en) | 2013-03-22 | 2018-02-06 | The University Of Tokyo | Aptamer to il-17 and use thereof |
| CN104623637A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术(上海)有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CN104311670B (zh) * | 2014-04-23 | 2017-05-17 | 哈尔滨博翱生物医药技术开发有限公司 | 针对IL‑17和TNFα的融合多肽及其应用 |
| AU2015269412B2 (en) | 2014-06-04 | 2020-03-12 | Exicure Operating Company | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| EP3183007B1 (en) | 2014-08-19 | 2020-06-17 | Northwestern University | Protein/oligonucleotide core-shell nanoparticle therapeutics |
| WO2016081911A2 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| EP3247796A4 (en) | 2015-01-14 | 2018-07-11 | Exicure, Inc. | Nucleic acid nanostructures with core motifs |
| EP3250927B1 (en) * | 2015-01-28 | 2020-02-19 | H. Hoffnabb-La Roche Ag | Gene expression markers and treatment of multiple sclerosis |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| US9512229B2 (en) * | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| JP2018527016A (ja) * | 2015-06-24 | 2018-09-20 | オックスフォード バイオダイナミックス リミテッド | 染色体相互作用の検出 |
| CN105420238A (zh) * | 2015-09-08 | 2016-03-23 | 中国农业科学院兰州兽医研究所 | 靶向抑制小鼠白细胞介素17A基因的序列siRNA-136 |
| CN105420237A (zh) * | 2015-09-08 | 2016-03-23 | 中国农业科学院兰州兽医研究所 | 靶向抑制小鼠白细胞介素17A基因的序列siRNA-180 |
| WO2017181143A1 (en) | 2016-04-15 | 2017-10-19 | Generon (Shanghai) Corporation, Ltd. | Use of il-22 in treating necrotizing enterocolitis |
| CA3023451A1 (en) * | 2016-05-06 | 2017-11-09 | Exicure, Inc. | Liposomal spherical nucleic acid (sna) constructs presenting antisense oligonucleotides (aso) for specific knockdown of interleukin 17 receptor mrna |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| NZ755416A (en) | 2016-12-19 | 2023-05-26 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
| WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| EP4106794A4 (en) | 2020-02-19 | 2024-03-20 | Evive Biotechnology (Shanghai) Ltd | METHOD FOR TREATING TRANSPLANT AND HOST DISEASE |
| KR20230017211A (ko) * | 2020-04-30 | 2023-02-03 | 얀센 파마슈티카 엔.브이. | Il-17 경로의 조절인자를 식별하는 방법 |
| MX2024001877A (es) | 2021-08-10 | 2024-02-28 | Kymab Ltd | Tratamiento de dermatitis atopica. |
| CN113817058B (zh) * | 2021-09-30 | 2023-05-26 | 港科鹏禾生物(苏州)有限公司 | 一种抗人il-17rc的单克隆抗体及其应用 |
| CN116063493B (zh) * | 2022-07-22 | 2023-09-01 | 贵州省赛尔生物科技有限公司 | 包含抗体和间充质干细胞外泌体的药物组合物及其制备方法 |
| CN116024212B (zh) * | 2022-07-29 | 2026-05-26 | 硅羿科技(上海)有限公司 | 抑制IL-25基因表达的siRNA及其应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737323A (en) * | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| GB8927546D0 (en) | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| GB2279725A (en) | 1993-07-09 | 1995-01-11 | Pall Corp | Combined check and pressure-relief valve |
| US5830877A (en) | 1993-08-26 | 1998-11-03 | The Regents Of The University Of California | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory |
| US5399677A (en) | 1993-12-07 | 1995-03-21 | Genetics Institute, Inc. | Mutants of bone morphogenetic proteins |
| US5516964A (en) | 1994-01-21 | 1996-05-14 | Sun Company, Inc. (R&M) | Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal |
| ES2229264T5 (es) * | 1995-03-23 | 2009-12-17 | Immunex Corporation | Receptor il-17. |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6074849A (en) | 1995-07-19 | 2000-06-13 | Genetics Institute, Inc. | Polynucleotides encoding human CTLA-8 related proteins |
| US6902735B1 (en) * | 1995-07-19 | 2005-06-07 | Genetics Institute, Llc | Antibodies to human IL-17F and other CTLA-8-related proteins |
| US5707829A (en) | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
| ATE239041T1 (de) * | 1996-02-09 | 2003-05-15 | Basf Ag | Humane antikörper welche an humanen tnfalpha binden |
| EP1015488B1 (en) * | 1997-09-17 | 2009-09-09 | Human Genome Sciences, Inc. | Interleukin-17 receptor-like protein |
| US6350892B1 (en) * | 1997-09-23 | 2002-02-26 | Bristol-Myers Squibb Company | Trifluoromethyl ketone analogs as selective cPLA2 inhibitors |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6218371B1 (en) | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| ES2292242T5 (es) * | 1998-05-15 | 2011-05-04 | Genentech, Inc. | Utilizaciones terapéuticas de polipéptidos homólogos de il-17. |
| BR0009323A (pt) | 1999-03-25 | 2002-01-08 | Knoll Gmbh | Anticorpos humanos que ligam a il-12 humana e métodos para a produção |
| JP2003527104A (ja) * | 1999-12-23 | 2003-09-16 | ジェネンテック・インコーポレーテッド | Il−17相同的ポリペプチドとその治療上の用途 |
| US20040043397A1 (en) * | 2000-01-11 | 2004-03-04 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| CA2425506A1 (en) * | 2000-10-18 | 2002-08-01 | Immunex Corporation | Methods for treating rheumatoid arthritis using il-17 antagonists |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20040058445A1 (en) | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
| US20070160576A1 (en) * | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
| DK1641822T3 (da) * | 2003-07-08 | 2013-07-22 | Genentech Inc | Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf. |
| EP1765865A2 (en) * | 2004-06-10 | 2007-03-28 | ZymoGenetics, Inc. | Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation |
| MX2007001509A (es) * | 2004-08-05 | 2007-03-27 | Wyeth Corp | Antagonismo de la actividad del receptor de interleuquina 21. |
| WO2006088925A2 (en) * | 2005-02-14 | 2006-08-24 | Wyeth | Use of il17-f in diagnosis and therapy of airway inflammation |
| DK1879573T3 (da) | 2005-05-10 | 2013-02-25 | Incyte Corp | Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf |
| TW200902064A (en) * | 2007-03-28 | 2009-01-16 | Wyeth Corp | Methods and compositions for modulating IL-17F/IL-17A biological activity |
-
2006
- 2006-02-14 CN CNA2006800125231A patent/CN101218254A/zh active Pending
- 2006-02-14 CA CA002596509A patent/CA2596509A1/en not_active Abandoned
- 2006-02-14 KR KR1020077018688A patent/KR20070107703A/ko not_active Withdrawn
- 2006-02-14 WO PCT/US2006/005111 patent/WO2006088833A2/en not_active Ceased
- 2006-02-14 JP JP2007555332A patent/JP2008532936A/ja not_active Withdrawn
- 2006-02-14 TW TW095104914A patent/TW200641353A/zh unknown
- 2006-02-14 GT GT200600065A patent/GT200600065A/es unknown
- 2006-02-14 MX MX2007009811A patent/MX2007009811A/es unknown
- 2006-02-14 BR BRPI0606991-6A patent/BRPI0606991A2/pt not_active IP Right Cessation
- 2006-02-14 EP EP06734991A patent/EP1848743A2/en not_active Ceased
- 2006-02-14 PE PE2006000175A patent/PE20061391A1/es not_active Application Discontinuation
- 2006-02-14 AU AU2006214473A patent/AU2006214473A1/en not_active Abandoned
- 2006-02-14 AR ARP060100516A patent/AR052289A1/es unknown
- 2006-02-14 EP EP10176925A patent/EP2322553A3/en not_active Withdrawn
- 2006-02-14 RU RU2007129263/13A patent/RU2007129263A/ru not_active Application Discontinuation
- 2006-02-14 CN CN2011100361519A patent/CN102178953A/zh active Pending
-
2007
- 2007-07-30 IL IL184933A patent/IL184933A0/en unknown
- 2007-08-07 CR CR9291A patent/CR9291A/es not_active Application Discontinuation
- 2007-08-07 NO NO20074053A patent/NO20074053L/no not_active Application Discontinuation
-
2008
- 2008-08-21 US US12/196,117 patent/US20090142806A1/en not_active Abandoned
-
2010
- 2010-06-30 US US12/827,199 patent/US20110033451A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007129263A (ru) | Антитела к интерлейкину-17f и другие антагонисты опосредуемой il-17f передачи сигналов и их применение | |
| Menegatti et al. | Anti-TNF therapy in spondyloarthritis and related diseases, impact on the immune system and prediction of treatment responses | |
| Hawkes et al. | Psoriasis pathogenesis and the development of novel targeted immune therapies | |
| Brzustewicz et al. | The role of cytokines in the pathogenesis of rheumatoid arthritis–Practical and potential application of cytokines as biomarkers and targets of personalized therapy | |
| Williams et al. | Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases | |
| Gaffen et al. | IL-23-IL-17 immune axis: discovery, mechanistic understanding, and clinical testing | |
| US6183951B1 (en) | Methods of diagnosing clinical subtypes of crohn's disease with characteristic responsiveness to anti-Th1 cytokine therapy | |
| McLean et al. | Targeting interleukins for the treatment of inflammatory bowel disease—what lies beyond anti-TNF therapy? | |
| AU2016210996B2 (en) | Therapeutic target and biomarker in IBD | |
| AU2007261019A1 (en) | Methods of modulating IL-22 and IL-17 | |
| TW200902064A (en) | Methods and compositions for modulating IL-17F/IL-17A biological activity | |
| CA2819538A1 (en) | Method for prognosticating the clinical response of a patient to b-lymphocyte inhibiting or depleting therapy in interferon driven diseases such as sle. | |
| Burman et al. | Cerebrospinal fluid cytokines after autologous haematopoietic stem cell transplantation and intrathecal rituximab treatment for multiple sclerosis | |
| IL298626A (en) | Cytokine conjugates | |
| CN116286844A (zh) | 人IL-1R1和人IL-1RAcP多肽片段组合的同源二聚体蛋白质与用途 | |
| WO2016191289A2 (en) | Biomarker for inflammatory disorders and uses thereof | |
| ZA200509143B (en) | GITR ligand and GITR ligand-related molecules and antibodies and uses thereof | |
| US20160077107A1 (en) | Personalised medicine | |
| Taylor et al. | Aetiopathology of rheumatoid arthritis | |
| US20260132191A1 (en) | Methods for modulating activity of il-18 for treatment of cd4+ t cell mediated autoimmunity and immunopathology | |
| WO2024102387A2 (en) | Fusion polypeptides and formulations thereof | |
| Yeo | Characterisation of cytokine expression in early synovitis and established rheumatoid arthritis | |
| Lampa | Studies of pharmacological interventions and pathogenesis of rheumatoid arthritis | |
| Alho | Mechanisms of post-transplant obliterative bronchiolitis: Study in a porcine heterotopic bronchial transplantation model | |
| Torheim | Chemokines in Wegener’s granulomatosis |